Cited 0 times in
Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 홍민희 | - |
dc.date.accessioned | 2024-01-03T00:35:05Z | - |
dc.date.available | 2024-01-03T00:35:05Z | - |
dc.date.issued | 2023-03 | - |
dc.identifier.issn | 2199-1154 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197306 | - |
dc.description.abstract | Background: Despite the dynamic treatment landscape for EGFR mutant-positive metastatic non-small cell lung cancer (EGFRm+ mNSCLC), most of the earlier studies have focused on US or Western populations. Objective: The objective of this study was to explore real-world treatment patterns and outcomes of South Korean patients with EGFRm+ mNSCLC. Methods: Retrospective chart review of adult patients with EGFRm+ mNSCLC who received systemic treatment between January-2019 and June-2019. Results: A total of 162 patients were included from 21 hospitals, with a median follow-up of 15.6 months. Median age was 65.0 years, 22% had central nervous system metastasis, and 57% and 38% had exon 19 deletion and exon 21 L858R, respectively. Among 144 patients (89%) who received first-line EGFR-tyrosine kinase inhibitor, afatinib was most the common (44%), followed by gefitinib (28%) and erlotinib (13%). First-line chemotherapy was more common when an EGFR-mutation was detected after versus before first-line treatment initiation (31% vs 5%). Discontinuation of first-line treatment was mostly due to disease-progression (81%) and toxicity (7%). Among 58 (78%) patients who received second-line treatment, osimertinib was the most common (40%). Most (60%) patients reported ≥1 Grade ≥3 adverse event during first-line treatment. Following initiation of first-line treatment, physician visits and chest X-rays were the most frequent healthcare utilisation events. Rates of emergency-room visits and hospitalization were 12% and 16%, respectively, with a mean length-of-stay of 10.4 days. At 12 months, overall survival rate was 95%, and numerically worse for patients with exon 21 versus 19 mutations. Conclusions: Characteristics and clinical outcomes of Korean patients with EGFRm+ mNSCLC in real-world practice were comparable to those observed in clinical trials. As osimertinib was not reimbursed for first-line treatment before study completion, further investigation is warranted to explore evolving treatment practice. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Springer International Publishing | - |
dc.relation.isPartOf | DRUGS-REAL WORLD OUTCOMES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Cliff Molife | - |
dc.contributor.googleauthor | Jae Min Cho | - |
dc.contributor.googleauthor | Jennifer Lapthorn | - |
dc.contributor.googleauthor | Min Ju Kang | - |
dc.contributor.googleauthor | Yulia D'yachkova | - |
dc.contributor.googleauthor | Sangmi Kim | - |
dc.contributor.googleauthor | Sam Colman | - |
dc.contributor.googleauthor | Saerom Kim | - |
dc.contributor.googleauthor | Agota Szende | - |
dc.contributor.googleauthor | Ji Hyun Park | - |
dc.contributor.googleauthor | Hee Kyung Ahn | - |
dc.contributor.googleauthor | Min Hee Hong | - |
dc.contributor.googleauthor | Kaisa-Leena Taipale | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.identifier.doi | 10.1007/s40801-022-00344-0 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A04393 | - |
dc.relation.journalcode | J04424 | - |
dc.identifier.eissn | 2198-9788 | - |
dc.identifier.pmid | 36456850 | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.contributor.affiliatedAuthor | 홍민희 | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 131 | - |
dc.citation.endPage | 143 | - |
dc.identifier.bibliographicCitation | DRUGS-REAL WORLD OUTCOMES, Vol.10(1) : 131-143, 2023-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.